Large studies of NSCLC patients by next-generation sequencing (NGS) identified PIK3CA gene mutations in 3.7% of patients, with predominance for squamous cell carcinoma (8.9%) compared with adenocarcinoma (2.9%). This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.